Skip to main content
Retour
EYPT logo

EyePoint Pharmaceuticals, Inc.

Qualité des données : 100%
EYPT
NASDAQ Healthcare Biotechnology
12,59 €
▼ 0,24 € (-1,87%)
Cap. Boursière : 1,05B
Fourchette du Jour
12,07 € 12,77 €
Fourchette 52 Semaines
3,91 € 19,11 €
Volume
813 813
Moyenne 50J / 200J
15,09 € / 13,15 €
Clôture Précédente
12,83 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E -4,5 0,3
P/B 3,4 2,9
ROE % -72,2 3,7
Net Margin % -739,4 3,8
Rev Growth 5Y % -4,0 10,0
D/E 0,1 0,2

Objectif de Cours des Analystes

Hold
37,50 € +197.9%
Low: 36,00 € High: 39,00 €
BPA Prévisionnel
-3,22 €
CA Est.
3,8 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 2,88 €
0,54 € – 5,21 €
880 M 5
FY2029 0,87 €
0,17 € – 1,58 €
570 M 2
FY2028 -1,17 €
-2,25 € – 0,31 €
290 M 7

Points Clés

Revenue declined -4,00% annually over 5 years
Debt/Equity of 0,07 — conservative balance sheet
Negative free cash flow of -243,39M
Revenue growth is decelerating — 1Y growth trails 5Y average by 23,50%

Croissance

Revenue Growth (5Y)
-4,00%
Revenue (1Y)-27,50%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-72,19%
ROIC-55,85%
Net Margin-739,42%
Op. Margin-775,98%

Sécurité

Debt / Equity
0,07
Current Ratio8,88
Interest Coverage7376,79

Valorisation

P/E Ratio
-4,53
P/B Ratio3,43
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -27,50% Revenue Growth (3Y) -17,43%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -4,00% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 31,37M Net Income (TTM) -231,96M
ROE -72,19% ROA -63,73%
Gross Margin 93,41% Operating Margin -775,98%
Net Margin -739,42% Free Cash Flow (TTM) -243,39M
ROIC -55,85% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,07 Current Ratio 8,88
Interest Coverage 7376,79 Dividend Yield 0,00%
Valuation
P/E Ratio -4,53 P/B Ratio 3,43
P/S Ratio 33,48 PEG Ratio -0,16
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 1,05B Enterprise Value 969,36M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 31,37M 43,27M 46,02M 41,40M 36,94M
Net Income -231,96M -130,87M -70,80M -102,25M -58,42M
EPS (Diluted) -3,17 -2,32 -1,82 -2,74 -2,03
Gross Profit 29,31M 39,56M 41,39M 33,08M 28,76M
Operating Income -243,43M -145,85M -75,07M -99,64M -55,28M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 364,00M 418,47M 355,18M 180,36M 263,37M
Total Liabilities 57,88M 81,96M 88,86M 83,99M 78,99M
Shareholders' Equity 306,11M 336,50M 266,32M 96,37M 184,38M
Total Debt 20,77M 21,86M 4,91M 46,35M 39,20M
Cash & Equivalents 101,82M 99,70M 281,26M 95,63M 178,59M
Current Assets 328,66M 383,31M 344,80M 172,81M 237,75M
Current Liabilities 37,02M 49,05M 63,26M 34,54M 23,66M